Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma

DISEASE CHARACTERISTICS: * Histologically confirmed uterine leiomyosarcoma * Advanced, persistent, or recurrent disease * Documented disease progression * Measurable disease * At least 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR ≥ 10 mm by spiral CT scan * At least 1 target lesion * Tumors within a previously irradiated field are considered nontarget lesions * Ineligible for higher priority GOG protocols (i.e., any active phase III GOG protocol for the same patient population) PATIENT CHARACTERISTICS: Age * Adult Performance status * GOG 0-2 Life expectancy * Not specified Hematopoietic * Absolute neutrophil count ≥ 1,500/mm\^3 * Platelet count ≥ 100,000/mm\^3 Hepatic * Bilirubin ≤ 1.5 times upper limit of normal (ULN) * AST ≤ 2.5 times ULN * Alkaline phosphatase ≤ 2.5 times ULN Renal * Creatinine ≤ 1.5 times ULN Other * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No neuropathy (sensory or motor) \> grade 1 * No other invasive malignancy within the past 5 years except nonmelanoma skin cancer * No active infection requiring antibiotics * No known hypersensitivity to E. coli-derived proteins PRIOR CONCURRENT THERAPY: Biologic therapy * Not specified Chemotherapy * No prior cytotoxic chemotherapy for the malignancy Endocrine therapy * At least 1 week since prior hormonal therapy for the malignancy * Concurrent hormone replacement therapy allowed Radiotherapy * See Disease Characteristics * Recovered from prior radiotherapy Surgery * Recovered from prior surgery Other * Recovered from all other prior therapy * No prior cancer treatment that would preclude study treatment * No concurrent amifostine or other protective agents